Cadence Capital Management LLC lessened its stake in Flexion Therapeutics Inc (NASDAQ:FLXN) by 52.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 25,694 shares of the specialty pharmaceutical company’s stock after selling 28,308 shares during the quarter. Cadence Capital Management LLC’s holdings in Flexion Therapeutics were worth $643,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in FLXN. State Street Corp boosted its holdings in shares of Flexion Therapeutics by 66.3% in the second quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after buying an additional 549,948 shares during the period. Ardsley Advisory Partners acquired a new position in shares of Flexion Therapeutics in the second quarter valued at approximately $3,338,000. Gagnon Securities LLC acquired a new position in shares of Flexion Therapeutics in the third quarter valued at approximately $3,490,000. Pictet Asset Management Ltd. boosted its holdings in shares of Flexion Therapeutics by 27.8% in the third quarter. Pictet Asset Management Ltd. now owns 604,469 shares of the specialty pharmaceutical company’s stock valued at $14,616,000 after buying an additional 131,673 shares during the period. Finally, Uniplan Investment Counsel Inc. acquired a new position in shares of Flexion Therapeutics in the third quarter valued at approximately $2,996,000. Institutional investors own 72.18% of the company’s stock.

Flexion Therapeutics Inc (FLXN) opened at $23.69 on Wednesday. Flexion Therapeutics Inc has a 1-year low of $16.51 and a 1-year high of $32.25. The company has a market cap of $889.34, a price-to-earnings ratio of -6.73 and a beta of 0.91. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87.

In other news, insider Neil Bodick purchased 2,700 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were purchased at an average cost of $24.49 per share, with a total value of $66,123.00. Following the completion of the transaction, the insider now owns 64,605 shares of the company’s stock, valued at approximately $1,582,176.45. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 15.98% of the company’s stock.

Several research analysts recently commented on the stock. Zacks Investment Research cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Northland Securities restated a “buy” rating and set a $40.00 target price on shares of Flexion Therapeutics in a report on Friday, November 10th. BidaskClub cut shares of Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. Finally, Berenberg Bank assumed coverage on shares of Flexion Therapeutics in a report on Thursday, February 1st. They set a “buy” rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $99.11.

ILLEGAL ACTIVITY WARNING: “Flexion Therapeutics Inc (FLXN) Shares Sold by Cadence Capital Management LLC” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/02/14/flexion-therapeutics-inc-flxn-shares-sold-by-cadence-capital-management-llc.html.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.